4//SEC Filing
York Charles N II 4
Accession 0001655962-25-000006
CIK 0001845337other
Filed
Nov 17, 7:00 PM ET
Accepted
Nov 18, 7:02 PM ET
Size
20.7 KB
Accession
0001655962-25-000006
Insider Transaction Report
Form 4
York Charles N II
COO and CFO
Transactions
- Exercise/Conversion
Restricted Stock Unit (RSU)
2025-11-15−6,625→ 79,500 total→ Common Stock (6,625 underlying) - Exercise/Conversion
Restricted Stock Unit (RSU)
2025-11-15−2,250→ 9,000 total→ Common Stock (2,250 underlying) - Exercise/Conversion
Common Stock
2025-11-15+6,625→ 298,777 total - Exercise/Conversion
Restricted Stock Unit (RSU)
2025-11-15−1,375→ 0 total→ Common Stock (1,375 underlying) - Exercise/Conversion
Common Stock
2025-11-15+1,375→ 283,277 total - Exercise/Conversion
Common Stock
2025-11-15+2,250→ 285,527 total - Exercise/Conversion
Common Stock
2025-11-15+6,625→ 292,152 total - Sale
Common Stock
2025-11-17$8.91/sh−4,062$36,212→ 294,715 total - Exercise/Conversion
Restricted Stock Unit (RSU)
2025-11-15−6,625→ 53,000 total→ Common Stock (6,625 underlying)
Footnotes (6)
- [F1]Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration.
- [F2]Includes 3,902 shares of Common Stock acquired by the Reporting Person between May 12, 2023 and November 14, 2025 pursuant to the Issuer's employee stock purchase plan.
- [F3]The sale of shares is for the sole purpose of covering the Reporting Person's tax liability with respect to the settlement of RSUs.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold as part of block trades for multiple security holders of the Issuer at prices ranging from $8.545 to $9.305, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein with regard to the block trade.
- [F5]The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
- [F6]RSUs do not expire; they either vest or are canceled prior to the vesting date.
Documents
Issuer
Day One Biopharmaceuticals, Inc.
CIK 0001845337
Entity typeother
Related Parties
1- filerCIK 0001655962
Filing Metadata
- Form type
- 4
- Filed
- Nov 17, 7:00 PM ET
- Accepted
- Nov 18, 7:02 PM ET
- Size
- 20.7 KB